免疫检查点抑制剂应用于晚期胃癌治疗的研究进展

Progress of immune check-point inhibitors’application in advanced gastric cancer

我国属胃癌高发国家,且以进展期胃癌为主。以手术和化疗为主的多学科治疗无法有效改善晚期胃癌患者的预后。近年来,免疫检查点抑制剂类药物的疗效在诸多癌症中得到了证实,因此,该类药物在胃癌中的治疗效果也受到了广泛的关注。本文对近年来的相关研究成果进行综述,全面介绍了免疫检查点抑制剂类药物在胃癌治疗中的临床应用情况、联合用药情况以及不良反应。对于其他治疗均失败的晚期胃癌患者,PD-1抑制剂是一个可行的治疗选项,其代表药物派姆单抗是目前唯一被美国食品药品监督管理局批准应用于胃癌治疗的免疫抑制剂类药物,而我国国家食品药品监督管理总局尚未批准任何此类药物应用于胃癌的临床治疗。如何进一步提高治疗的客观缓解率,将会是后续临床和基础研究的一大焦点。

China is one of the countries with the highest prevalence of gastric cancer,who the majority gastric cancers are advanced stage diseases.Multi-disciplinary treatment including surgery and chemotherapy is not sufficient to effectively improve the prognosis of late-stage gastric cancer.In recent years,immune check-point inhibitor has gained promising results in assorted types of cancers.Therefore,its application in gastric cancer has drew increasing attention.This article will review recent clinical researches and introduced the current clinical application of immune check-point inhibitors in the treatment of gastric cancer.For late-stage gastric cancer patients after failed attempts of treatment by conventional chemotherapy,PD-1 inhibitor is a viable option.Pembrolizumab is currently the only PD-1 inhibitor approved by FDA for application in gastric cancer,whereas CFDA has not approved any immune check-point inhibitors for this purpose.One of the major focus of subsequent basic and clinical researches will be how to further increase the objective response rate of anti-PD-1 treatment.